AbbVie Inc. (ABBV)$215.70
Market Cap: 346.84 BCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for AbbVie Inc. (ABBV).
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
DCF ready
Valuation
22.8x
EV/FCF, 4.4% FCF yield
Quality
6.9%
ROIC, 29.1% FCF margin
Growth
6.0%
5Y sales (revenue) CAGR
Balance sheet
-19.7x
Debt/equity, 0.7x current ratio
Superinvestors
7
Top: Torray Funds (3.2%)
Strengths to research
- Free cash flow margin is healthy at 29.1%.
- Debt/equity looks manageable at -19.7x.
- 7 tracked superinvestors report a position.
- 10 annual periods are available for trend analysis.
Watchouts
- P/E is elevated at 91.4x.
- Current ratio is below 1 at 0.7x.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for ABBV.
Grade C
51
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| ABBV Target | AbbVie Inc. | $346.8B | 91.4x | 22.8x | 6.9% | 6.0% | 29.1% | N/A | 3.7x | N/A |
| JNJ | Johnson & Johnson | $372.9B | 21.2x | 20.0x | 21.8% | 2.7% | 20.9% | 67.9% | N/A | N/A |
| NVO | Novo Nordisk A S | $305.8B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| RHHBY | Roche Holding AG ADR | $265.2B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| RHHVF | Roche Holdings AG DIV RT | $263.8B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| NVS | Novartis AG | $223.3B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| MRK | Merck & Co. | $208.5B | 16.8x | 15.7x | 34.7% | 9.4% | 19.0% | N/A | N/A | N/A |
| LLY | Eli Lilly & Co. | $737.7B | 46.4x | 43.4x | 77.8% | 21.6% | 25.8% | N/A | N/A | N/A |
| AMGN | Amgen | $150.6B | 23.8x | 24.2x | 12.2% | 7.6% | 22.0% | N/A | 3.2x | N/A |
Financial Charts
No financial data available for ABBV (annual).
7 superinvestors own ABBV
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Torray Funds Torray Funds | 93,588 | $20M | 3.19% | 0.0% |
| Mairs & Power Growth Fund Mairs & Power Growth Fund | 45,317 | $10M | 0.10% | 0.0% |
| David Katz Matrix Asset Advisors | 39,175 | $9M | 0.78% | 0.0% |
| Thomas Russo Gardner Russo & Quinn | 12,410 | $3M | 0.03% | 0.0% |
| Jensen Investment Management Jensen Investment Management | 11,144 | $2M | 0.05% | 0.0% |
| Dodge & Cox Dodge & Cox | 10,393 | $2M | 0.00% | 0.0% |
| Bill Nygren Oakmark Select Fund | 2,682 | $583,000 | 0.00% | 0.0% |